PRISTIQExtended Release Tablets Shown To Significantly Reduce Number And Severity Of Moderate-To-Severe Hot Flashes Associated With Menopause (PFE)

Pfizer Inc. PFE today announced results from a Phase 3 12-week efficacy sub-study, which found that PRISTIQ, a serotonin-norepinephrine reuptake inhibitor, significantly reduced the number and severity of moderate-to-severe hot flashes in postmenopausal women. The data were presented at the 59th Annual Clinical Meeting of the American College of Obstetricians and Gynecologists in Washington, D.C.